Pulmatrix (NASDAQ:PULM) Shares Cross Above 50 Day Moving Average – Here’s What Happened

Posted by Latisha Jones on Aug 5th, 2026

Pulmatrix, Inc. (NASDAQ:PULM – Get Free Report) shares crossed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $1.58 and traded as high as $1.72. Pulmatrix shares last traded at $1.66, with a volume of 17,326 shares traded.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Pulmatrix from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 30th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Get Our Latest Report on Pulmatrix

Pulmatrix Stock Performance

The company has a 50 day moving average of $1.58 and a 200 day moving average of $1.81. The stock has a market capitalization of $6.06 million, a price-to-earnings ratio of -1.35 and a beta of 1.91.

Pulmatrix (NASDAQ:PULM – Get Free Report) last announced its quarterly earnings data on Friday, May 15th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Pulmatrix stock. DRW Securities LLC acquired a new stake in Pulmatrix, Inc. (NASDAQ:PULM – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 20,505 shares of the biotechnology company’s stock, valued at approximately $46,000. Institutional investors and hedge funds own 11.84% of the company’s stock.

Pulmatrix Company Profile

(Get Free Report)

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).